Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies

Eric NormanArticles, FoCUS

Pharmaceutical Executive, January 9, 2020
Matt W. Courtney, Jane F. Barlow, Mark Trusheim

The reimbursement of emerging durable and potentially curative cell and gene therapies challenge U.S. payers due to their high upfront costs. In addition, the lack of long-term clinical durability data amplifies uncertainties which complicate payer coverage and reimbursement determinations. These cell and gene therapy characteristics could negatively impact patient access and ultimately, future developer innovation. 

Read the article